> To be clear: whoever gets heart inflammation from Moderna would’ve almost certainly got it worse from Covid. The issue arises from the spike protein itself. That’s why we don’t see myocarditis from non-MRNA vaccines like Astra Zeneca. https://twitter.com/joshzepps/status/1486213480823017472?s=2... Edit : Consider readied the entire Twitter thread. https://www.abc.net.au/radio/sydney/programs/afternoons/myoc... > It…
> That’s why we don’t see myocarditis from non-MRNA vaccines like Astra Zeneca. Does the AstraZeneca vaccine not include the spike protein? I thought it included the whole virus including the spike protein.
I think it is therefore more likely that adaptive immune system is involved because it has ability to remember.
Now is it possible that spike protein itself or lipid shell is causing this based on incidence rate differences between 3 vaccines?
Hard to say.
The amount of spike protein produced is in correlation with amount of mRNA entering cells. The amount of mRNA entering cells is 3x higher with Moderna vaccine than with Pfizer vaccine and it appears that it is similar on both shots (first and second). But the amount of mRNA (converted from adenovirus DNA) entering cells with the second AZ shot is probably lower than on the first shot because there is also some immunity against the adenovirus and the dose size is the same.
This is in correlation with the amount of antibodies produced by these vaccines.
This is the not contradicting with the observation so far.
But it could be also lipid cell that has been found to cause inflammation. Considering the high amount of antibodies generated on the second vaccination, it is plausible that the lipid shells are not attacked by the immune system directly. But it might be possible that the cells are attacked after lipid shells have merged with their membranes.
There are few ways to find how what is most likely happening.
First is to hope that protein based vaccine from Novavax will be used by meaningful amount to detect proper incidence rates. When it is spike protein itself then we should see also high incidence rate on second vaccination.
The second option is to analyze mixed vaccinations where first vaccination was done with adenovirus vaccine and the second one with mRNA vaccine. It is not perfect setup but it might provide some additional information.
Third option is to use a mouse model similar to one in previous study where mouse were intravenously injected with mRNA vaccines. Repeat the study with mRNA vaccine, placebo (saline solution), dummy lipid shells and protein vaccines (might be necessary to do the study without and with the adjuvant).